Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Determination of the heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin in plasma by liquid chromatography-electrospray mass spectrometry.
Hwang K, Scripture CD, Gutierrez M, Kummar S, Figg WD, Sparreboom A. Hwang K, et al. Among authors: gutierrez m. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 2;830(1):35-40. doi: 10.1016/j.jchromb.2005.10.019. Epub 2005 Nov 2. J Chromatogr B Analyt Technol Biomed Life Sci. 2006. PMID: 16260191
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ. Kummar S, et al. Among authors: gutierrez me. Eur J Cancer. 2010 Jan;46(2):340-7. doi: 10.1016/j.ejca.2009.10.026. Epub 2009 Nov 27. Eur J Cancer. 2010. PMID: 19945858 Free PMC article. Clinical Trial.
A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas.
Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, Kummar S, Gutierrez M, Crandon S, Zein WM, Jain L, Mannargudi B, Figg WD, Houk BE, Shnaidman M, Brega N, Giaccone G. Rajan A, et al. Among authors: gutierrez m. Clin Cancer Res. 2011 Nov 1;17(21):6831-9. doi: 10.1158/1078-0432.CCR-11-0821. Epub 2011 Sep 9. Clin Cancer Res. 2011. PMID: 21908572 Free PMC article. Clinical Trial.
Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies.
Kummar S, Gutierrez M, Gardner ER, Donovan E, Hwang K, Chung EJ, Lee MJ, Maynard K, Kalnitskiy M, Chen A, Melillo G, Ryan QC, Conley B, Figg WD, Trepel JB, Zwiebel J, Doroshow JH, Murgo AJ. Kummar S, et al. Among authors: gutierrez m. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5411-7. doi: 10.1158/1078-0432.CCR-07-0791. Clin Cancer Res. 2007. PMID: 17875771 Clinical Trial.
Pharmacogenetically driven patient selection for a first-in-human phase I trial of batracylin in patients with advanced solid tumors and lymphomas.
Kummar S, Gutierrez ME, Anderson LW, Klecker RW Jr, Chen A, Murgo AJ, Doroshow JH, Collins JM. Kummar S, et al. Among authors: gutierrez me. Cancer Chemother Pharmacol. 2013 Oct;72(4):917-23. doi: 10.1007/s00280-013-2244-4. Epub 2013 Aug 3. Cancer Chemother Pharmacol. 2013. PMID: 23912694 Free PMC article. Clinical Trial.
3,108 results